Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) announced it will present 8 abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Dec. 10–11, 2025, covering MRD, germline testing, somatic profiling, and polygenic risk.

Key highlights include new data on the Precise Molecular Residual Disease (MRD) Test—a tumor-informed, WGS-based assay with custom selection of up to 1,000 variants and reported ultra-sensitivity at low tumor fractions (RUO)—and updates to the MyRisk Hereditary Cancer Test expanded to 63 genes. Myriad will sponsor a Product Theater session on Dec. 10 (2:30–3:30 p.m. CST) and host a booth (#1414) during exhibition hours.

Key Figures

Number of abstracts 8 abstracts Breast cancer and MRD presentations at 2025 SABCS

Targeted variants up to 1,000 variants Custom selection for Precise MRD whole-genome-based assay

Genes in MyRisk panel 63 genes Updated MyRisk Hereditary Cancer Test panel across multiple cancers

Cancer types covered more than 11 cancer types MyRisk hereditary cancer coverage breadth described in SABCS release

Product Theater session time 2:30–3:30 p.m. SABCS Product Theater session on Dec. 10, 2025

Exhibit booth number Booth 1414 Myriad exhibition space at 2025 SABCS

Presentation dates Dec. 10–11, 2025 Timing of multiple SABCS poster and session presentations

Market Reality Check

$7.23 Last Close

Volume Volume 891,138 is below the 20-day average of 1,153,927 ahead of this SABCS update. normal

Technical Shares at $7.07 are trading slightly above the 200-day MA of $6.84, but remain 57.47% below the 52-week high.

Peers on Argus

Peers show mixed moves: CDNA (+2.11%), PSNL (+1.45%) versus CSTL (−2.78%) and NEO (−2.42%), suggesting MYGN’s reaction is more stock-specific than sector-driven.

Common Catalyst Limited peer news overlap; one peer (CSTL) also reported cancer-focused testing news, but broader sector catalysts are not evident.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 25	AI risk platform	Positive	-3.9%	AI and genetics collaboration for integrated breast cancer risk assessment.
Nov 11	Investor conferences	Neutral	+3.1%	Participation in two late-2025 investor healthcare conferences.
Nov 10	Test expansion	Positive	+2.9%	Expanded MyRisk hereditary cancer panel to 63 genes across 11+ cancers.
Nov 06	Conference studies	Positive	-3.8%	11 new research studies showcased at genetic counselors conference.
Nov 03	Q3 2025 earnings	Neutral	+1.7%	Reported Q3 revenue, losses, liquidity, and reiterated 2025 guidance.

Pattern Detected

Recent news often drew meaningful price moves, with product/partnership updates sometimes selling off despite positive positioning, while conference and earnings items leaned modestly positive.

Recent Company History

Over the past months, Myriad reported Q3 2025 results on Nov 3, showing ongoing losses but reiterated full-year guidance and maintained liquidity. Subsequent news emphasized genetic testing expansion and visibility: highlighting 11 studies at a genetic counselors conference on Nov 7–8, adding genes to the MyRisk panel on Nov 10, and attending investor conferences later in November. An AI-enabled breast risk collaboration was unveiled on Nov 25. Today’s SABCS abstracts and MRD data build directly on this strategy of deepening oncology test capabilities and clinical relevance.

Market Pulse Summary

This announcement highlights Myriad’s focus on breast oncology through 8 SABCS abstracts spanning MRD, germline, somatic, and polygenic risk work. The Precise MRD test and expanded 63-gene MyRisk panel reinforce a strategy centered on comprehensive cancer risk and monitoring. Set against recent earnings showing ongoing losses and leadership changes, investors may track how these research-use offerings translate into clinical adoption, revenue contribution, and operational progress over coming quarters.

Key Terms

molecular residual disease (MRD) medical

"New data will be presented about Precise® Molecular Residual Disease (MRD) Test"

Molecular residual disease (MRD) is the tiny number of cancer cells that remain in a patient after treatment, detected by highly sensitive genetic or molecular tests that can find one cancer cell among thousands or millions of normal cells. MRD matters to investors because it helps predict the chance of relapse and influences whether additional treatment is given; MRD signals are increasingly used as early clinical trial or regulatory endpoints, so positive or negative MRD results can materially affect the market value of diagnostics and therapies—similar to an early warning that shapes future decisions.

circulating tumor DNA (ctDNA) medical

"ultrasensitive and quantitative ctDNA testing, as we observed noteworthy correspondence"

Circulating tumor DNA (ctDNA) are tiny fragments of genetic material shed by cancer cells into the bloodstream, detectable with a blood test often called a liquid biopsy. For investors, ctDNA matters because it can enable earlier, less invasive detection of cancer, track how well treatments are working, and guide drug development and diagnostic products—factors that can drive demand, regulatory decisions, and company valuations in oncology-related markets.

whole genome sequencing (WGS) technical

"uses whole genome sequencing (WGS) to achieve ultra-sensitivity"

Whole genome sequencing (WGS) is a laboratory process that reads an individual's complete DNA instruction book to identify all genetic differences and features, much like scanning every page of a manual rather than just a few chapters. For investors it matters because WGS underpins diagnostic tests, drug discovery and personalized treatments, shaping potential revenue streams, development timelines, regulatory scrutiny and privacy risks across healthcare and biotech investments.

polygenic risk medical

"combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover insights"

A polygenic risk score summarizes a person’s inherited likelihood of developing a disease by adding up the small effects of many different genes, like creating a credit score from lots of tiny financial factors. Investors care because these scores can change demand for diagnostics, drugs, preventive services, and insurance products by identifying groups with higher or lower health needs, which affects revenue, market size and regulatory scrutiny in healthcare-related businesses.

homologous recombination deficiency (HRD) medical

"only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned"

Homologous recombination deficiency (HRD) is a failure in a cell's main system for fixing broken DNA, like a city's main bridge repair crew being unable to fix critical damage. Investors care because HRD status can predict which tumors will respond to certain targeted therapies and companion diagnostic tests, shaping drug development, regulatory approvals, treatment guidelines, and the commercial value of oncology drugs and diagnostics.

PARP inhibitors medical

"for selecting patients with ovarian cancer who may benefit from PARP inhibitors"

PARP inhibitors are a class of cancer drugs that block an enzyme cells use to repair damaged DNA, effectively preventing cancer cells from fixing themselves and causing them to die. Investors watch them because their clinical approvals, safety profiles, patent status, and tests that identify which patients will benefit determine market size and revenue potential—much like backing a tool that only works on certain problems but can be very valuable when it does.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) regulatory

"include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)"

Authoritative, regularly updated recommendations created by clinical experts that describe best practices for diagnosing and treating cancer. Think of them as a detailed roadmap or recipe doctors and hospitals use to choose therapies, tests and follow-up care; adoption of these guidelines affects which drugs and procedures become standard, how quickly new treatments are used, and whether insurers pay for them — all factors that influence a company’s commercial prospects in oncology.

tumor-informed assay medical

"Precise Molecular Residual Disease (MRD) Test is a tumor-informed assay that uses"

A tumor-informed assay is a personalized test that first reads the unique DNA 'fingerprint' of a patient’s tumor and then looks for matching DNA fragments in the blood to detect tiny amounts of cancer left after treatment or to monitor response. Investors care because these tests can offer more accurate, early detection of recurrence than one-size-fits-all tests, potentially driving clinical adoption, recurring revenue, and competitive advantage in diagnostics markets.

AI-generated analysis. Not financial advice.

New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium^® (SABCS).

The company will share the latest advances in the MyRisk^® Hereditary Cancer Test that support guideline-driven treatment decisions. Additionally, the company is presenting data on its Precise^® Molecular Residual Disease (MRD) Test, an ultrasensitive, second-generation pan-tumor MRD test that is especially impactful for low-tumor-shedding cancers, such as breast cancer. It has high sensitivity and specificity at low tumor fraction.¹

“I am thrilled that we are sharing some very strong data at SABCS from multiple breast-cancer studies that used Precise MRD,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Each study showcases the benefit of ultrasensitive and quantitative ctDNA testing, as we observed noteworthy correspondence with clinical outcomes of interest. I’m also pleased that, in addition to MRD studies, we are sharing data about germline testing, somatic testing, and polygenic risk assessment, all areas of excellence for Myriad that underscore our commitment to serving the cancer care continuum.”

Myriad will sponsor a session at the Product Theater, where Gregory Vidal, MD, PhD, associate professor at the University of Tennessee Health Science Center, and Sara Mokhtary-Myers, MS, CGC, certified genetic counselor and Genetics Program Coordinator at Texas Oncology, will discuss the evolving role of tumor genomic and germline testing in breast cancer care. The session will be held on Wednesday, Dec. 10, 2:30–3:30 p.m.

Myriad Genetics Presentations
Personalized Whole-Genome-Based ctDNA Dynamics During Neoadjuvant Therapy Across Breast Cancer Subtypes: Early Insights From MONITOR-Breast
Abstract #3552, Presentation # PS1-13-11
Wednesday, Dec. 10, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Julia Foldi, MD, PhD, University of Pittsburgh Medical Center

Ultra-sensitive Molecular Residual Disease Detection in Breast Cancer Using Whole-Genome Sequencing-Based Personalized ctDNA Panels: Preliminary Results from the MONSTAR-SCREEN-3 Project
Presentation # PS2-09-07
Wednesday, Dec. 10, 5:00-6:30 pm (CST), Exhibit Hall
Presenter: Yoichi Naito, National Cancer Center Hospital East, Kashiwa, Japan

Ultrasensitive ctDNA-based MRD monitoring predicts relapse in postoperative HR+ inflammatory breast cancer
Abstract #1012, Presentation # PS4-02-02
Thursday, Dec. 11, 5:00-6:30 pm (CST), Exhibit Hall
Presenter: Ranjan Upadhyay MD, PhD, Anderson Cancer Center

Ancestry-specific prevalence of pathogenic variants among patients with breast cancer who do not meet guidelines for genetic testing
Abstract #858, Presentation #PS3-02-30
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics

Enhancing breast cancer risk assessment in a community imaging center to identify high-risk patients and guide screening and management
Abstract #202, Presentation # PS3-02-13
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Tammy McKamie, MSN, RN, ACGN, OCN, Myriad Genetics

Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in women of self-reported Black/African ancestry
Abstract #1222, Presentation # PS3-01-03
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics

Co-occurring pathogenic variants in patients with breast cancer
Abstract #1570, Presentation # PS3-02-07
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Kallie Woods, MS, CGC, Myriad Genetics

Tumor genomic profiling results in breast cancer patients: A comprehensive analysis from a laboratory research registry
Abstract #888, Presentation # PS2-10-26
Wednesday, Dec. 10, 5:00-6:30 pm (CST), Exhibit Hall
Presenter: Gregory Vidal MD, PhD, West Cancer Center and Regional One Health

Myriad Genetics at Booth 1414
In addition to data presentations, Myriad will welcome attendees to its booth (#1414) during exhibition hours. Among the Myriad products highlighted in the company’s 2025 SABCS exhibit are:

• Precise Molecular Residual Disease (MRD) Test is a tumor-informed assay that uses whole genome sequencing (WGS) to achieve ultra-sensitivity. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity.¹ The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance. This test is currently available for research use only (RUO) and not available for clinical use.
• MyRisk Hereditary Cancer Test is a leading hereditary cancer test that has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®)² and guidelines from American Society of Clinical Oncology (ASCO). These genes are associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The updated MyRisk panel now includes 63 carefully selected genes across more than 11 cancer types, reflecting Myriad’s commitment to meeting evolving clinical needs and delivering clinical value at every step of the cancer care continuum.
• MyRisk Test with RiskScore^® combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover insights that gene testing alone may not provide, helping offer more information to support patient decisions in breast cancer risk assessment and management.
• MyChoice^® CDx Test is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in ASCO guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors.³ By determining comprehensive HRD status, the MyChoice CDx Test helps expand access to targeted therapy in both early and late-line settings.

¹ Acevedo, A. et al. Analytical validation of a high-definition tumor-informed MRD assay demonstrates robust detection at low tumor fractions common in breast cancer. Poster presented at the San Antonio Breast Cancer Symposium (SABCS) Dec 10-13, 2024.
² NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
³ Tew WP, Lacchetti C, Birrer MJ, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468-3493

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the company’s expectation that, in addition to MRD studies, it will share data about germline testing, somatic testing, and polygenic risk assessment, which are areas of excellence for the company that underscore its commitment to serving the cancer care continuum, and the company’s belief that the expansion of the MyRisk Hereditary Cancer Test to include genes referenced in NCCN Guidelines and guidelines from ASCO will support the company’s goal that each addition to the panel provides meaningful insights for patient care and reflects the company’s commitment to meeting evolving clinical needs and delivering value across the cancer care continuum. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com

FAQ

When and where will Myriad Genetics present the 8 abstracts at SABCS 2025 for MYGN?

Presentations are scheduled at the 2025 San Antonio Breast Cancer Symposium on Dec. 10–11, 2025, with specific sessions listed across those dates.

What does Myriad say about the Precise MRD Test presented by MYGN at SABCS 2025?

Myriad describes Precise MRD as a tumor-informed, WGS-based assay with up to 1,000 targeted variants, ultra-sensitivity at low tumor fraction, and currently available for research use only (RUO).

How many genes are included in the updated MyRisk hereditary panel announced by MYGN?

The updated MyRisk hereditary cancer panel includes 63 genes referenced to NCCN and ASCO guidelines.

When is Myriad's Product Theater session at SABCS 2025 and who is presenting?

Myriad sponsors a Product Theater on Dec. 10, 2025, 2:30–3:30 p.m. CST, featuring Gregory Vidal, MD, PhD, and Sara Mokhtary-Myers, MS, CGC.

Is the Precise MRD Test described by MYGN cleared for clinical use?

No; the release states the Precise MRD Test is currently available for research use only (RUO) and not for clinical use.